Quantitative Systems Pharmacology (QSP) Summit 2022

Thursday, September 15th | Le Meridien Boston Cambridge

About the Event

The Quantitative Systems Pharmacology (QSP) Summit is a premier, free conference dedicated to fostering an active community of industry and academic participants interested in topics relevant to QSP. In its fifth year, the QSP Summit is a one-day event featuring talks from key industry and academic researchers, a poster session with awards, and networking time with peers.

qsp summit

 

Speakers

  • Abed Alnaif, PhD
    • Principal Scientist - Translational Quantitative Pharmacology at EMD Serono
  • Alison Betts, PhD
    • Vice President of Scientific Collaborations and Fellow of Modeling & Simulation at Applied BioMath
  • David de Graaf, PhD
    • Strategic Advisor at Abcuro, Inc. 
  • Nathan Higginson-Scott, PhD
    • Chief Technology Officer and SVP, Drug Creation at Seismic Therapeutic
  • Panteleimon Mavroudis, PhD
    • Senior Principal Scientist-Lab Head, Quantitative Pharmacology at Sanofi
  • Greg Moore, PhD
    • Director of Protein Engineering at Xencor
  • Tatiana Novobrantseva, PhD
    • Chief Scientific Officer, Immuno-oncology Research at Moderna
  • Hiroyuki Sayama, PhD
    • Research Fellow at Astellas Pharma
  • Brian Schmidt, PhD
    • Executive Director, Head QSP & PBPK at Bristol Myers Squibb
  • Mark Stroh, PhD
    • Vice President and Head, Clinical Pharmacology at Intellia Therapeutics
  • Leah Terrian
    • PhD Graduate Student at Michigan State University

Agenda

The QSP Summit agenda is subject to change. Download the agenda here

Start Time (ET) Event
8:45 AM

Breakfast and registration

9:15 AM

Opening remarks

9:30 AM

Greg Moore, PhD
Director of Protein Engineering at Xencor

"Enabling selective activity of CD28 and TGFbR2 bispecific antibodies through cis or trans avidity engineering"

10:00 AM

Abed Alnaif, PhD
Principal Scientist - Translational Quantitative Pharmacology at EMD Serono

"Predicting the incidence proportion of drug-induced serotonin syndrome-associated tremors using a model-based meta-analysis"

10:30 AM

Break and poster viewing session

11:00 AM

Mark Stroh, PhD
Vice President and Head, Clinical Pharmacology at Intellia Therapeutics

"Less may be more for TTR in ATTR: model-predicted outcomes of TTR reductions"

11:30 AM

Lightning Talks
Three, ten-minute talks selected from abstract submissions

Ali Khalilimeybodi, PhD
Postdoctoral Researcher at UC San Diego

"Signaling network model of cardiomyocyte morphological changes in familial cardiomyopathy"

Frank Schaefer, PhD
Postdoctoral Researcher at MIT

"Differentiation of discontinuities in ordinary differential equations arising from dosing"

Monish Kumar
PhD Student at University of Houston

"Quantitative modeling of host infection to guide design of antiviral therapeutics and vaccines"

12:00 PM

Lunch and poster viewing session

1:00 PM

Panteleimon Mavroudis, PhD
Senior Principal Scientist - Lab Head, Quantitative Pharmacology at Sanofi

"Model-Based Approaches to Guide Feasibility and Design of Multispecific Biotherapeutics"

1:30 PM

Leah Terrian
PhD Graduate Student at Michigan State University

"Cell Differentiation as a Critical State Transition"

2:00 PM

Alison Betts, PhD
Vice President of Scientific Collaborations and Fellow of Modeling & Simulation at Applied BioMath

"More than the sum of their parts: integrating data and knowledge of ADCs in a QSP platform model to predict efficacy and toxicity"

2:30 PM

Break and poster viewing session 

3:00 PM

Brian Schmidt, PhD
Executive Director, Head QSP & PBPK at Bristol Myers Squibb

"Increasing the probability of success: supporting a diverse pipeline with a variety of mechanistic modeling approaches"

3:30 PM

Hiroyuki Sayama, PhD
Research Fellow at Astellas Pharma

"A Quantitative Systems Pharmacology Approach in Oncology Drug Development - Virtual Clinical Trial Simulation for a KRASG12C inhibitor"

4:00 PM

Break 

4:15 PM

QSP Summit Executive Roundtable
Pharma and biotech executives who think like mechanistic modelers, work with mechanistic modelers, but are not mechanistic modelers

David de Graaf, PhD
Strategic Advisor at Abcuro, Inc.

Nathan Higginson-Scott, PhD
Chief Technology Officer and SVP, Drug Creation at Seismic Therapeutic

Tatiana (Tanya) Novobrantseva, PhD
Chief Scientific Officer, Immuno-oncology Research at Moderna

5:15 PM

Closing remarks and poster awards

5:30 PM QSP Summit concludes

Register for the QSP Summit

Your Safety is Our Top Priority

We care about the health and safety of our attendees and will have several hand sanitizing stations at the event. Additionally, by registering for the QSP Summit, you are agreeing to abide by our Code of Conduct, as follows:

  • You have been fully vaccinated against COVID-19
  • You will not attend if you have tested positive for COVID-19 (within the past 5 days) and/or if you feel sick day of the event
  • You will be respectful of your fellow attendees

We are looking forward to a healthy event!